Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Nutr Cancer. 2009;61(2):206–215. doi: 10.1080/01635580802419749

Table 4.

Association of 10-yr supplemental zinc use assessed at baseline with prostate cancer by stage and grade among 35,244 men in VITAL cohort.

10-yr avg. zinc
(mg/day)b 		Grade
Gleason score 2-6
 Gleason score
7-10
Cases Adjusted HRa 95% CI Cases Adjusted HRa 95% CI
None 157 1.0 122 1.0
0.1-7.5 102 0.88 0.60-1.29 81 0.85 0.55-1.33
7.51-15 137 0.99 0.66-1.50 99 0.85 0.53-1.38
>15 73 0.93 0.60-1.45 43 0.70 0.41-1.19
p-trend 0.91 0.21
Stage
Local
 Regional/Distant
Cases Adjusted HRa 95% CI Cases Adjusted HRa 95% CI
None 233 1.0 51 1.0
0.1-7.5 154 0.91 0.67-1.24 31 0.58 0.26-1.28
7.51-15 205 1.01 0.72-1.41 33 0.50 0.21-1.19
>15 107 0.94 0.65-1.34 11 0.34 0.13-1.09
p-trend 0.98 0.04
a

Multivariate HRs adjusted for education, race, family history, PSA-test within the 2 years prior to baseline, and current multivitamin use

b

10-yr average zinc includes all individual zinc supplements and multivitamins